Maximum Strength Pepcid AC Approval Calls For Postmarketing Study
This article was originally published in The Tan Sheet
Johnson & Johnson/Merck is required to submit a protocol by late March 2004 for a postmarket study on Pepcid AC (famotidine) (10 mg) and new Maximum Strength Pepcid AC (20 mg), following FDA approval of the latter Sept. 24
You may also be interested in...
New heartburn prevention/relief product Maximum Strength Pepcid AC will hit shelves Oct. 17, following FDA approval of the new dosage Sept. 24, according to Johnson & Johnson/Merck
Johnson & Johnson/Merck is preparing to introduce a prescription strength version of Pepcid (famotidine) for over-the-counter sale
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC